Japan's latest batch of approval recommendations include global-first nods for anselamimab for kappa light chain amyloidosis and gefurulimab for generalized myasthenia gravis.
Japan's latest batch of approval recommendations include global-first nods for anselamimab for kappa light chain amyloidosis and gefurulimab for generalized myasthenia gravis.